(Total Views: 1162)
Posted On: 08/10/2019 10:05:38 PM
Post# of 154009
Allergan's acquired Tobira in November 2016:
Allerganwill acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.
Allerganwill acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.
(0)
(0)
